Clearstead Advisors, LLC Cogent Biosciences, Inc. Call Options Transaction History
Clearstead Advisors, LLC
- $7.4 Billion
- Q3 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding COGT
# of Institutions
208Shares Held
127MCall Options Held
1.39MPut Options Held
460K-
Deerfield Management Company, L.P. (Series C) New York, NY9.05MShares$304 Million2.42% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA9MShares$302 Million28.14% of portfolio
-
Kynam Capital Management, LP Princeton, NJ7.89MShares$265 Million9.57% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.76MShares$260 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$244 Million0.0% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $2.21B
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...